PSPetr Smirnov

Petr Smirnov

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Petr Smirnov has a total of 112 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Similarity metric learning on perturbational datasets improves functional identification of perturbations

    by Ian Smith, Petr Smirnov, Benjamin Haibe-Kains

    Analysis of high-throughput perturbational datasets, including the Next Generation Connectivity Map (L1000) and the Cell Painting projects, uses similarity metrics to identify perturbations or disease states that induce similar changes in the biological feature space. Similarities among perturbations are then used to identify drug mechanisms of action, to nominate therapeutics for a particular disease, and to construct bio-logical networks among perturbations and genes. Standard similarity metrics include correlations, cosine distance and gene set enrichment methods, but these methods operate on the measured features without refinement by transforming the measurement space. We introduce Perturbational Metric Learning (PeML), a weakly supervised similarity metric learning method to learn a data-driven similarity function that maximizes discrimination of replicate signatures by transforming the biological measurements into an intrinsic, dataset-specific basis. The learned similarity functions show substantial improvement for recovering known biological relationships, like mechanism of action identification. In addition to capturing a more meaningful notion of similarity, data in the transformed basis can be used for other analysis tasks, such as classification and clustering. Similarity metric learning is a powerful tool for the analysis of large biological datasets.


  • Open Access

    Data from Bimodal Gene Expression in Patients with Cancer Provides Interpretable Biomarkers for Drug Sensitivity

    by Wail Ba-Alawi, Sisira Kadambat Nair, Bo Li, Anthony Mammoliti, Petr Smirnov, Arvind Singh Mer, Linda Z. Penn, Benjamin Haibe-Kains

    Identifying biomarkers predictive of cancer cell response to drug treatment constitutes one of the main challenges in precision oncology. Recent large-scale cancer pharmacogenomic studies have opened new avenues of research to develop predictive biomarkers by profiling thousands of human cancer cell lines at the molecular level and screening them with hundreds of approved drugs and experimental chemical compounds. Many studies have leveraged these data to build predictive models of response using various statistical and machine learning methods. However, a common pitfall to these methods is the lack of interpretability as to how they make predictions, hindering the clinical translation of these models. To alleviate this issue, we used the recent logic modeling approach to develop a new machine learning pipeline that explores the space of bimodally expressed genes in multiple large in vitro pharmacogenomic studies and builds multivariate, nonlinear, yet interpretable logic-based models predictive of drug response. The performance of this approach was showcased in a compendium of the three largest in vitro pharmacogenomic datasets to build robust and interpretable models for 101 drugs that span 17 drug classes with high validation rates in independent datasets. These results along with in vivo and clinical validation support a better translation of gene expression biomarkers between model systems using bimodal gene expression.Significance:A new machine learning pipeline exploits the bimodality of gene expression to provide a reliable set of candidate predictive biomarkers with a high potential for clinical translatability.

  • Open Access

    Data from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

    by Arvind S. Mer, Wail Ba-Alawi, Petr Smirnov, Yi X. Wang, Ben Brew, Janosch Ortmann, Ming-Sound Tsao, David W. Cescon, Anna Goldenberg, Benjamin Haibe-Kains

    Identifying robust biomarkers of drug response constitutes a key challenge in precision medicine. Patient-derived tumor xenografts (PDX) have emerged as reliable preclinical models that more accurately recapitulate tumor response to chemo- and targeted therapies. However, the lack of computational tools makes it difficult to analyze high-throughput molecular and pharmacologic profiles of PDX. We have developed Xenograft Visualization & Analysis (Xeva), an open-source software package for in vivo pharmacogenomic datasets that allows for quantification of variability in gene expression and pathway activity across PDX passages. We found that only a few genes and pathways exhibited passage-specific alterations and were therefore not suitable for biomarker discovery. Using the largest PDX pharmacogenomic dataset to date, we identified 87 pathways that are significantly associated with response to 51 drugs (FDR < 0.05). We found novel biomarkers based on gene expressions, copy number aberrations, and mutations predictive of drug response (concordance index > 0.60; FDR < 0.05). Our study demonstrates that Xeva provides a flexible platform for integrative analysis of preclinical in vivo pharmacogenomics data to identify biomarkers predictive of drug response, representing a major step forward in precision oncology.Significance:A computational platform for PDX data analysis reveals consistent gene and pathway activity across passages and confirms drug response prediction biomarkers in PDX.See related commentary by Meehan, p. 4324

  • Open Access

    Data from Modeling Cellular Response in Large-Scale Radiogenomic Databases to Advance Precision Radiotherapy

    by Venkata Sk. Manem, Meghan Lambie, Ian Smith, Petr Smirnov, Victor Kofia, Mark Freeman, Marianne Koritzinsky, Mohamed E. Abazeed, Benjamin Haibe-Kains, Scott V. Bratman

    Radiotherapy is integral to the care of a majority of patients with cancer. Despite differences in tumor responses to radiation (radioresponse), dose prescriptions are not currently tailored to individual patients. Recent large-scale cancer cell line databases hold the promise of unravelling the complex molecular arrangements underlying cellular response to radiation, which is critical for novel predictive biomarker discovery. Here, we present RadioGx, a computational platform for integrative analyses of radioresponse using radiogenomic databases. We fit the dose–response data within RadioGx to the linear-quadratic model. The imputed survival across a range of dose levels (AUC) was a robust radioresponse indicator that correlated with biological processes known to underpin the cellular response to radiation. Using AUC as a metric for further investigations, we found that radiation sensitivity was significantly associated with disruptive mutations in genes related to nonhomologous end joining. Next, by simulating the effects of different oxygen levels, we identified putative genes that may influence radioresponse specifically under hypoxic conditions. Furthermore, using transcriptomic data, we found evidence for tissue-specific determinants of radioresponse, suggesting that tumor type could influence the validity of putative predictive biomarkers of radioresponse. Finally, integrating radioresponse with drug response data, we found that drug classes impacting the cytoskeleton, DNA replication, and mitosis display similar therapeutic effects to ionizing radiation on cancer cell lines. In summary, RadioGx provides a unique computational toolbox for hypothesis generation to advance preclinical research for radiation oncology and precision medicine.Significance:The RadioGx computational platform enables integrative analyses of cellular response to radiation with drug responses and genome-wide molecular data.

  • Open Access

    Supplementary File 3 from Modeling Cellular Response in Large-Scale Radiogenomic Databases to Advance Precision Radiotherapy

    by Venkata Sk. Manem, Meghan Lambie, Ian Smith, Petr Smirnov, Victor Kofia, Mark Freeman, Marianne Koritzinsky, Mohamed E. Abazeed, Benjamin Haibe-Kains, Scott V. Bratman

    Supplementary File 3 shows gene expression correlation with radioresponse under simulated oxic and hypoxic conditions.

  • Open Access

    Supplementary File 1 from Modeling Cellular Response in Large-Scale Radiogenomic Databases to Advance Precision Radiotherapy

    by Venkata Sk. Manem, Meghan Lambie, Ian Smith, Petr Smirnov, Victor Kofia, Mark Freeman, Marianne Koritzinsky, Mohamed E. Abazeed, Benjamin Haibe-Kains, Scott V. Bratman

    Supplementary File 1 shows transcriptional pathways associated with the radioresponse indicators SF2 or AUC.

  • Open Access

    Supplementary Data from Modeling Cellular Response in Large-Scale Radiogenomic Databases to Advance Precision Radiotherapy

    by Venkata Sk. Manem, Meghan Lambie, Ian Smith, Petr Smirnov, Victor Kofia, Mark Freeman, Marianne Koritzinsky, Mohamed E. Abazeed, Benjamin Haibe-Kains, Scott V. Bratman

    The Supplementary Data file contains 10 supplementary figures and 3 supplementary tables.

  • Open Access

    Supplementary Data from Bimodal Gene Expression in Patients with Cancer Provides Interpretable Biomarkers for Drug Sensitivity

    by Wail Ba-Alawi, Sisira Kadambat Nair, Bo Li, Anthony Mammoliti, Petr Smirnov, Arvind Singh Mer, Linda Z. Penn, Benjamin Haibe-Kains

    Supplementary Data from Bimodal Gene Expression in Patients with Cancer Provides Interpretable Biomarkers for Drug Sensitivity

  • Open Access

    Supplementary Data File 3 from Integrative Pharmacogenomics Analysis of Patient-Derived Xenografts

    by Arvind S. Mer, Wail Ba-Alawi, Petr Smirnov, Yi X. Wang, Ben Brew, Janosch Ortmann, Ming-Sound Tsao, David W. Cescon, Anna Goldenberg, Benjamin Haibe-Kains

    Pathway stability in PDXs across passages for Hallmark pathway set.

  • Open Access

    Supplementary Table from Bimodal Gene Expression in Patients with Cancer Provides Interpretable Biomarkers for Drug Sensitivity

    by Wail Ba-Alawi, Sisira Kadambat Nair, Bo Li, Anthony Mammoliti, Petr Smirnov, Arvind Singh Mer, Linda Z. Penn, Benjamin Haibe-Kains

    Supplementary Table from Bimodal Gene Expression in Patients with Cancer Provides Interpretable Biomarkers for Drug Sensitivity